ERBB2 and cancer: Previous population-based studies have found significant disparities between Black and White women in overall and breast cancer-specific mortality among select stages and subtypes of breast cancer, but not among all stages and subtypes.[7,8] Specifically, these studies found that Black women had worse cancer-specific survival[7] and a higher risk of cancer-specific mortality[8] in stage II and III of the HR+/HER2− subtype.[7,8] stage II of the HR+/HER2+ subtype,[7] stage IV of the HR−/HER2+ subtype,[7] and stages II[7] and III[8] of the TN subtype.